Historical Context
For a comprehensive chronological account from the 1934 Los Angeles outbreak through the 2025 DecodeME GWAS — including the nomenclature disputes, PACE trial controversy, and the psychosomatic-to-biological transition — see History of ME/CFS. This section summarizes key historical context relevant to the introduction.
1 Key Outbreaks and Case Clusters
ME/CFS was first recognized through epidemic outbreaks affecting medical personnel and communities, initially misdiagnosed as atypical poliomyelitis.
Los Angeles County Hospital (1934). The first documented outbreak occurred at Los Angeles County Hospital in 1934, affecting 198 staff members (Gilliam 1938). Initially diagnosed as atypical poliomyelitis, subsequent analysis revealed a distinct clinical pattern with prominent neurological symptoms and prolonged post-infectious disability.
Iceland/Akureyri (1948–1949). An outbreak in Akureyri, Iceland affected 1,106 people and gave the disease one of its early names: “Iceland disease” (Sigurdsson et al. 1950). Sigurdsson described a triphasic course — acute flu-like phase, subacute neurological phase, and chronic fatigue phase — a pattern that remains central to clinical descriptions today.
Royal Free Hospital, London (1955). The most thoroughly documented outbreak occurred at the Royal Free Hospital from July to November 1955, affecting 292 staff members (255 hospitalized) (Medical Staff of the Royal Free Hospital 1957). The hospital’s medical staff introduced the name “myalgic encephalomyelitis” in their 1957 BMJ report; E.D. Acheson later added “benign” in his 1959 synthesis of 14 worldwide epidemics (Acheson 1959) — a qualifier intended to distinguish ME from poliomyelitis (which killed or paralyzed) but later abandoned as the chronic, disabling nature of the illness became apparent. Dr. Melvin Ramsay, head of Infectious Diseases at Royal Free, became a lifelong advocate and developed the first clinical criteria for ME, emphasizing muscle fatigability with prolonged recovery and neurological dysfunction (Ramsay 1986). Ramsay later published long-term follow-up documentation that validated Acheson’s synthesis, documenting objective findings — abnormal muscle biopsy, persistent neurological signs, exercise intolerance — that could not be explained psychosomatically.
Lake Tahoe/Incline Village (1984–1985). An outbreak in the Lake Tahoe region documented by physicians Paul Cheney and Daniel Peterson affected an estimated 259 patients, with 160 residents of Incline Village affected by winter 1985 (Buchwald et al. 1992). The CDC investigation, led by Gary Holmes, found elevated Epstein-Barr virus (EBV) antibodies but concluded there was insufficient evidence for an EBV-specific epidemic. This investigation led directly to the first formal case definition — the Holmes criteria of 1988 — and the official replacement of “myalgic encephalomyelitis” with “chronic fatigue syndrome” in CDC nomenclature (Holmes et al. 1988).
2 Evolution of Diagnostic Criteria
Diagnostic criteria for ME/CFS have evolved substantially, with increasing recognition of post-exertional malaise as the cardinal feature.
Holmes/CDC Criteria (1988). The first formalized definition required new-onset debilitating fatigue lasting at least six months that was not resolved by bed rest and reduced activity by at least 50%, plus 6 of 11 symptom criteria and 2 of 3 physical criteria, or 8 of 11 symptom criteria (Holmes et al. 1988). This established the six-month duration threshold still used today and formally introduced the name “chronic fatigue syndrome” in CDC nomenclature. The criteria did not require post-exertional malaise as a defining feature, and the 11-symptom checklist captured heterogeneous populations.
Oxford Criteria (1991). The UK responded with the Oxford criteria, the broadest case definition ever proposed for CFS/ME (Sharpe et al. 1991). Requiring only fatigue as the principal symptom with definite onset plus functional impairment, the Oxford criteria explicitly allowed inclusion of patients with concurrent psychiatric diagnoses and did not require PEM, pain, or neurological symptoms. These criteria later became central to the PACE trial controversy: by casting the widest possible net, they permitted inclusion of patients whose primary problem may have been depression or deconditioning rather than ME/CFS.
Fukuda Criteria (1994). Developed by the International Chronic Fatigue Syndrome Study Group, these criteria required six or more months of chronic fatigue of new or definite onset, not substantially alleviated by rest, causing substantial reduction in activities, plus four of eight specific symptoms: unrefreshing sleep, post-exertional malaise, myalgia, arthralgia, new headaches, sore throat, tender lymphadenopathy, and impaired memory or concentration (Fukuda et al. 1994). The Fukuda criteria became the most widely used research standard for two decades, though they were limited by not requiring PEM.
Canadian Consensus Criteria (2003). The Canadian Consensus Criteria represented a paradigm shift by requiring post-exertional malaise as a mandatory criterion, described as “pathologically slow recovery, usually 24 hours or longer” (Carruthers et al. 2003). These criteria also required sleep dysfunction, pain, and symptoms from multiple categories including neurological, cognitive, autonomic, neuroendocrine, and immune manifestations. Studies demonstrate that patients meeting Canadian Consensus Criteria have more severe presentations and greater functional impairment than those meeting Fukuda criteria alone.
International Consensus Criteria (2011). An international panel of 26 experts from 13 countries achieved 100% consensus via Delphi methodology on criteria that emphasized “myalgic encephalomyelitis” terminology and required symptoms from four domains: post-exertional neuroimmune exhaustion, neurological impairment, immune/gastrointestinal/genitourinary impairments, and energy production/transportation impairments (Carruthers et al. 2011). These criteria identify a more homogeneous patient population with greater functional impairments.
Institute of Medicine Criteria (2015). The Institute of Medicine (now National Academy of Medicine) proposed simplified diagnostic criteria and the name “Systemic Exertion Intolerance Disease” (SEID), though this name was not widely adopted (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015). The IOM criteria require three symptoms present at least 50% of the time with moderate, substantial, or severe intensity: substantial reduction in pre-illness activities, unrefreshing sleep, and post-exertional malaise, plus either cognitive impairment or orthostatic intolerance. Critically, this report declared ME/CFS “a serious, chronic, complex systemic disease” requiring proper medical recognition.
3 Changes in Medical Understanding
The medical understanding of ME/CFS has undergone dramatic shifts, moving from psychogenic theories toward recognition as a biological disease.
The Psychogenic Era. In 1970, psychiatrists McEvedy and Beard published analyses of 15 ME outbreaks (including Royal Free 1955) in the British Medical Journal, concluding they represented “mass hysteria” based partly on the preponderance of female patients and institutional settings (McEvedy and Beard 1970). This analysis was conducted without examining patients or consulting treating physicians. McEvedy’s argument rested on three assumptions: that female predominance indicated psychogenic vulnerability (rather than immunological susceptibility, consistent with women’s higher rates of most autoimmune diseases), that absence of mortality implied non-organic etiology, and that negative laboratory tests ruled out biological disease (a logical error — absence of evidence for a known pathogen is not evidence of absence of disease). Ramsay, who had personally examined Royal Free patients during the 1955 outbreak, published a book-length rebuttal in 1986 documenting long-term follow-up with objective findings — abnormal muscle biopsy, persistent neurological signs, exercise intolerance — that could not be explained psychosomatically (Ramsay 1986). The Ramsay-McEvedy debate crystallized a deeper epistemological tension: when standard tests are normal, does the abnormality lie in the patient’s psychology or in the sensitivity of the tests? Subsequent mathematical modeling of outbreak data has demonstrated that the epidemiological patterns fit infectious disease models, mathematically refuting the hysteria hypothesis (Underhill and Baillod 2021).
The PACE Trial and Institutional Reversals. The largest ME/CFS treatment trial ever conducted (PACE, n=641), published in The Lancet in 2011, reported that cognitive behavioral therapy and graded exercise therapy produced recovery rates of 22% (White et al. 2011). Independent re-analysis revealed that mid-trial changes to recovery thresholds had inflated results — under the original protocol definitions, recovery rates were approximately 6% in all groups with no meaningful advantage for any treatment (Wilshire et al. 2018). Patient surveys found that 54–74% reported worsening from graded exercise therapy (Geraghty, Hann, and Kurtev 2019). This prompted a series of institutional reversals: the CDC removed graded exercise therapy from its clinical guidance (2017), Cochrane withdrew and revised its systematic review (2019), and NICE guideline NG206 explicitly recommended against graded exercise therapy (2021) (National Institute for Health and Care Excellence 2021). The PACE trial has become the most-cited cautionary tale in ME/CFS research methodology, demonstrating that patient-led FOIA requests and independent statisticians — not institutional quality control — were required to force data release and re-analysis Patient-Generated Knowledge and Citizen Science.
Return to Biological Investigation. The Lake Tahoe outbreak reinvigorated biological research, leading to investigations of viral triggers, immune dysfunction, and neurological abnormalities through the 1990s and 2000s. The Canadian Consensus Criteria (2003) and International Consensus Criteria (2011) explicitly framed ME/CFS as a neuroimmune disease with objective physiological abnormalities.
The 2015 IOM Report. The Institute of Medicine’s comprehensive review concluded that “ME/CFS is a serious, chronic, complex systemic disease that often can profoundly affect the lives of patients” (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015). The committee emphasized that ME/CFS is a “medical—not psychiatric or psychological—illness” and called for increased research funding and physician education.
The 2024 NIH Deep Phenotyping Study. The landmark NIH intramural study by Walitt et al. (2024) using deep phenotyping provided evidence for biological abnormalities across multiple systems in ME/CFS (Walitt et al. 2024). This study demonstrated brain dysfunction (decreased temporoparietal junction activity), immune exhaustion (exhausted T-cells and chronic B-cell activation), and neurochemical abnormalities (low catecholamines in cerebrospinal fluid). Standard clinical laboratory panels remained normal — validating what every outbreak from 1934 to 1985 had reported. The NIH officially stated that “ME/CFS is a serious, chronic, systemic disease… researchers have found differences in the brains and immune systems of people with post-infectious ME/CFS” (National Institutes of Health 2024). However, the study was controversial in its interpretive framing: the lead authors emphasized an “effort preference” model — suggesting that patients’ reduced motor output reflected altered decision-making about effort rather than physiological impairment — despite documenting physiological abnormalities that equally supported a metabolic or neuroinflammatory interpretation. This framing triggered widespread criticism from patient organizations, researchers, and clinicians, and highlighted a recurring pattern: objective biological findings can be co-opted by preexisting psychosomatic interpretive frameworks, even by investigators themselves.
The COVID-19 Catalyst. The COVID-19 pandemic paradoxically accelerated ME/CFS research by creating millions of long COVID patients with overlapping symptom profiles. The recognition that 10–30% of COVID-19 survivors develop persistent symptoms, with up to 51% of long COVID patients meeting ME/CFS diagnostic criteria (Jason et al. 2025), brought unprecedented attention and funding to post-infectious illness research. This convergence has produced several advances:
- Shared research infrastructure: Long COVID research programs (RECOVER, PHOSP-COVID) have included ME/CFS comparison groups, generating high-quality data on both conditions.
- Treatment crossover: Interventions studied for long COVID, including low-dose naltrexone (LDN), have shown promise in ME/CFS populations. LDN, which modulates microglial activation and neuroinflammation, emerged from long COVID clinical experience and is now being systematically studied in ME/CFS (Bolton, Chapman, and Van Marwijk 2020).
- Biomarker discovery: The urgency of the long COVID crisis has accelerated biomarker research applicable to both conditions, including markers of immune exhaustion, microclotting, and mitochondrial dysfunction.
- Public recognition: The visibility of long COVID has reduced stigma around ME/CFS and increased acceptance that post-infectious chronic illness is a legitimate medical phenomenon.
The connection between long COVID and ME/CFS has validated decades of patient advocacy and shifted the research paradigm toward viewing ME/CFS as the prototypical post-acute infection syndrome.